Exactech (EXAC) Reports In-Line Q2 EPS

Exactech (NASDAQ: EXAC) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $66.1 million versus the consensus estimate of $67.74 million.

GUIDANCE:

Exactech sees Q4 2017 EPS of $1.25-$1.29, versus the consensus of $1.30. Exactech sees Q4 2017 revenue of $267-271 million, versus the consensus of $270.32 million.

For earnings history and earnings-related data on Exactech (EXAC) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance